A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY efficacy and safety at scale. IDE034 is in open-label phase 1 ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results